peptide evidence atlas

Peptide·modified or textual

ATLPC0035775

ATLPC0035775

fCYwOrnTPenT-NH2

Routes

Compare in workbench Download release API JSON

Length
13 aa

Coveragecounts only · not riskATLPC0035775

Measurements
9
Endpoints
1
Domains
1/5
Products
—

No matrix stability evidence
No clearance evidence
No immunogenicity context
No sequence liability cues

Jump to domain

Open the matching evidence section below

All evidence index · 9

Exposure / Absorption

No evidence

Distribution / Barrier

Metabolic & Proteolytic Stability

No evidence

Excretion / Persistence

No evidence

Toxicity / Safety

No evidence

01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity view

A peptidoform is one specific molecular form of the peptide — its sequence plus the modifications at given positions (HUPO-PSI term). This view preserves the reported terminal groups, residue modifications, and stereo markers from the source notation.

fCYwOrnTPenT-NH2

Identity summarySpecific molecular form represented

Identity status: Specific molecular form represented
Residues: 13
Peptidoform features: 8
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0038912	—	—	—	Notation only	—

Residue view

Residue display

13 residues

F1C2Y3W4X5R6N7T8P9E10N11T12X13

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

Reported residue markerpos 1

Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Reported residue markerpos 4

Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Non-standard residue tokenpos 5

X

Reported token O is not one of the 20 standard residue symbols in this display.

Reported residue markerpos 6

Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Reported residue markerpos 7

Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Reported residue markerpos 10

Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Reported residue markerpos 11

Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Non-standard residue tokenpos 13

X

Reported token NH2 is not one of the 20 standard residue symbols in this display.

Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

modified or textual

Parent-residue sequence

Residue string used for positional interpretation when available.

FCYWXRNTPENTX

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached

3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

03

Distribution / Barrier

9 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

9

Complete canonical measurements and observations attached to this domain.

Endpoint scope

1

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

5

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

4

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBBB penetration

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

5

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

4

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

0

Review before analysis

Records whose present structure does not establish a safe analysis role.

0

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

BBB penetration9 records · 5 matched-context · 4 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	23.71 %	Eligible when experimental context matches	Capillary depletion · blood-brain barrier	Result: Reported point value · Molecular form: not reported · % capillary · NA · Source: Primary reference linked	Reference
2	76.29 %	Eligible when experimental context matches	Capillary depletion · blood-brain barrier	Result: Reported point value · Molecular form: not reported · % parenchyma · NA · Source: Primary reference linked	Reference
3	900 min	Eligible when experimental context matches	HPLC · blood-brain barrier	Result: Reported point value · Molecular form: not reported · t1/2, brain · NA · Source: Primary reference linked	Reference
4	2.4 x 10^-4 mL/g/min	Eligible when experimental context matches	Intravenous injection (multiple time regression) · blood-brain barrier	Result: Reported point value · Molecular form: not reported · Kin · non saturable · Source: Primary reference linked	Reference
5	0.01894 mL/g	Eligible when experimental context matches	Intravenous injection (multiple time regression) · blood-brain barrier	Result: Reported point value · Molecular form: not reported · Vi · non saturable · Source: Primary reference linked	Reference
6	900 min	Interpret as reported	Not specified	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
7	200 min	Interpret as reported	Not specified	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
8	0.01894 mL/g	Interpret as reported	NA · NA · blood-brain barrier	Result: Reported point value · Molecular form: not reported · Route: Intravenous · non saturable · Source: Primary reference linked	Reference
9	2.4 x 10^-4 mL/g/min	Interpret as reported	NA · NA · blood-brain barrier	Result: Reported point value · Molecular form: not reported · Route: Intravenous · non saturable · Source: Primary reference linked	Reference

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

0

artificial membrane

Caco-2

0

cell monolayer

MDCK

0

cell monolayer

RRCK

0

cell monolayer

BBB

9

barrier evidence

04

Evidence landscape

9 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

0 evidence records

0

0

0

0

Distribution / Barrier

9 evidence records

5

4

0

0

Metabolic & Proteolytic Stability

0 evidence records

0

0

0

0

Excretion / Persistence

0 evidence records

0

0

0

0

Toxicity / Safety

0 evidence records

0

0

0

0

Endpoint distribution

Top evidence-bearing endpoint questions.

Blood Brain Barrier Penetration

9

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

4

Matrix / stability

3

Unspecified

2

Traceability

Reference-link availability for measurement-level audit.

Linked reference

9

Not linked

0

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReference

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	900 min	Reported point value	Interpret as reported	Not specified	Not specified	Reference Primary reference linked
2	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	0.019 mL/g	Reported point value	Interpret as reported	NA · blood-brain barrier	Route: Intravenous	Reference Primary reference linked
3	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	2.4 x 10^-4 mL/g/min	Reported point value	Interpret as reported	NA · blood-brain barrier	Route: Intravenous	Reference Primary reference linked
4	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	200 min	Reported point value	Interpret as reported	Not specified	Not specified	Reference Primary reference linked
5	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	0.019 mL/g	Reported point value	Eligible when experimental context matches	Intravenous injection (multiple time regression) · blood-brain barrier	Not specified	Reference Primary reference linked
6	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	900 min	Reported point value	Eligible when experimental context matches	HPLC · blood-brain barrier	Not specified	Reference Primary reference linked
7	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	2.4 x 10^-4 mL/g/min	Reported point value	Eligible when experimental context matches	Intravenous injection (multiple time regression) · blood-brain barrier	Not specified	Reference Primary reference linked
8	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	23.71 %	Reported point value	Eligible when experimental context matches	Capillary depletion · blood-brain barrier	Not specified	Reference Primary reference linked
9	Distribution / Barrier Distribution	Blood Brain Barrier Penetration	76.29 %	Reported point value	Eligible when experimental context matches	Capillary depletion · blood-brain barrier	Not specified	Reference Primary reference linked

1–9 / 9

06

Identity & reference map

9 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary1 reference group

Identity type: reported modified sequence
Reported notation: 0
Reference groups: 1
Measurements: 9
ATL peptide ID: ATLPC0035775

Identity concordance

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 9

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 9

Different notation

Reported notation does not resolve to the current display sequence.

0 / 9

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

9 / 9

Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity

fCYwOrnTPenT-NH2

Reported names

No distinct human-readable aliases are exposed.

Reference map1 reference group

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	Distribution Blood Brain Barrier Penetration	No reported alias	9 identity 9 evidence

07

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0035775
Identity type: reported modified sequence
ADMET endpoints: 1
Evidence records: 9
Reference groups: 1
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

GET /api/v1/peptides/ATLPC0035775

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0035775' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'